Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses
From The ONS Podcast · · 37 min
This plays from the publisher's own server. We do not host a copy.
Description
"You also want to deal with patient preferences. We do want to get their disease under control. We want to make them live a long, good quality of life. But do they want to come to the clinic once a week? Is it a far distance? Is geography a problem? Do they prefer not taking oral chemotherapies at home? We have to think about what the patient's preferences are to some degree and kind of incorporate that in our decision-making plan for treatments for relapsed and refractory myeloma," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma treatment considerations.
Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 6, 2027. Ann McNeill has disclosed a speakers bureau relationship with Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Learning outcome: Learners will report an increase in knowledge related to the treatment of multiple myeloma.
Episode Notes
- Complete this evaluation for free NCPD.
- ONS Podcast™ episodes: - Episode 398: An Overview of Multiple Myeloma for Oncology Nurses
- Episode 395: Pharmacology 101: Monoclonal Antibodies
- Episode 372: Pharmacology 101: Proteasome Inhibitors
- ONS Voice articles: - Effective Care Transitions Are Essential for New Multiple Myeloma Treatments
- New Multiple Myeloma Treatments Present New Challenges in Side Effect Management
- Reduce Racial Barriers and Care Inequities for Black and African American Patients With Multiple Myeloma
- ONS Voice FDA approval alerts
- ONS Voice oncology drug reference sheets: - Belantamab mafodotin-blmf
- Daratumumab
- Motixafortide
- Selinexor
- Clinical Journal of Oncology Nursing articles: - Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
- Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles
- Oncology Nursing Forum article: Facilitators of Multiple Myeloma Treatment: A Qualitative Study
- ONS books: - Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition)
- Multiple Myeloma: A Textbook for Nurses (third edition)
- ONS course: ONS Hematopoietic Stem Cell Transplantation™
- ONS Huddle Cards: - Financial Toxicity
- Hematopoietic Stem Cell Transplantation (HSCT)
- Monoclonal Antibodies
- ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library
- American Society of Clinical Oncology (ASCO)–Ontario Health: Treatment of Multiple Myeloma Living Guideline
- International Myeloma Foundation: - Clinical Trials Fact Sheets
- Clinical Trial Support (https://www.myeloma.org/sparkcures/)
- Resource Library (https://www.myeloma.org/publications-videos)
- Multiple Myeloma Research Foundation resource: Treatments for Multiple Myeloma
To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/).
To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.
To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.
Highlights From This Episode
"Typically for our first-line therapies, we use certain classes of drugs and some of them are proteasome inhibitors like bortezomib and carfilzomib. We also have IMiDs or immunomodulatory agents like thalidomide, lenalidomide, and pomalidomide. We have monoclonal antibodies, anti-CD38 monoclonal…